All In Biotech

Drug Trial Radar · NCT07622329

A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

4

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Sep 2, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
The General Hospital of Western Theater CommandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, recommended subsequent dose, pharmacokinetic profile, and preliminary efficacy of JCXH-213 in adult patients with primary immune thrombocytopenia (ITP) who are refractory or relapsed after treatment with corticosteroids and second-line therapies. The study consists of a screening period, treatment period, end-of-treatment visit, safety follow-up, and study withdrawal visit. Two dose groups are planned: 2 mg and 4 mg, with 2 patients to be enrolled in each dose group. During the treatment period, JCXH-213 at the assigned dose will be administered once every other day for a total of 7 doses. Assessments for safety and efficacy will be conducted according to the study schedule. After the last dose, patients will undergo an end-of-treatment visit and safety follow-up until the end of the study.

Conditions

  • Thrombocytopenic Purpura, Immune

Interventions

  • JCXH-213Drug

    An mRNA-LNP based in vivo CAR therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of JCXH-213Time frame: The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Hospital of Western Theater Command of PLA

    Chengdu, Chengdu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.